Newswire (Published: Friday, October 13, 2017, Received: Friday, October 6, 2017, 12:24:13 AM CDT)

Word Count: 433

Findings from University of Palermo Yields New Data on Prostate Cancer (Treatment with abiraterone in metastatic castration-resistant prostate cancer patients progressing after docetaxel: a retrospective study)

By a News Reporter-Staff News Editor at Drug Week -- Research findings on Oncology - Prostate Cancer are discussed in a new report. According to news originating from Palermo, Italy, by NewsRx correspondents, research stated, "The aim of this study was to evaluate abiraterone's efficacy in Italian patients affected with metastatic prostate cancer progressing after treatment with docetaxel. We conducted a retrospective analysis of 60 patients."

Our news journalists obtained a quote from the research from the University of Palermo, "Prostate-specific antigen (PSA) reduction in serum was the primary endpoint for evaluating the efficacy of abiraterone in combination with prednisone treatment, whereas reduced pain, safety, progression-free survival, response rate, and overall survival (OS) were secondary endpoints. A significant correlation was noticed between PSA response and OS. Further, the Index Bravais-Pearson (r) correlation allowed us to observe a significant negative interdependence between PSA response and reduction in pain of 0.57 (95% confidence interval: -0.30 to 0.80) (P= 0.005). Meanwhile, regression analysis revealed that PSA levels are predictive of OS. There was a positive correlation with OS, which showed a value of R-2 to 0.50 with a slope of 1.44 (P= 0.0021). Abiraterone is a well-tolerated and effective treatment modality for patients affected with metastatic castration-resistant prostate cancer."

According to the news editors, the research concluded: "The drug has a better tolerability profile, gives significant pain relief, and increases the survival rate."

For more information on this research see: Treatment with abiraterone in metastatic castration-resistant prostate cancer patients progressing after docetaxel: a retrospective study. Anti-Cancer Drugs, 2017;28(9):1047-1052. Anti-Cancer Drugs can be contacted at: Lippincott Williams & Wilkins, Two Commerce Sq, 2001 Market St, Philadelphia, PA 19103, USA. (Lippincott Williams and Wilkins - www.lww.com; Anti-Cancer Drugs - journals.lww.com/anti-cancerdrugs/pages/default.aspx)

The news correspondents report that additional information may be obtained from G. Cicero, University of Palermo, Dept. of Surg Oncol & Oral Sci, Sect Med Oncol, Palermo, Italy. Additional authors for this research include R. De Luca, L. Blasi, A. Pepe, C. Pavone, A. Simonato and F. Dieli (see also Oncology - Prostate Cancer).

Keywords for this news article include: Palermo, Italy, Europe, Prostate-Specific Antigen, Enzymes and Coenzymes, Drugs and Therapies, Prostatic Neoplasms, Mitotic Inhibitors, Docetaxel Therapy, Antineoplastics, Pharmaceuticals, Prostate Cancer, Oncology, University of Palermo.

Our reports deliver fact-based news of research and discoveries from around the world. Copyright 2017, NewsRx LLC

Companies

Lippincott Williams & Wilkins
Wolters Kluwer N.V.
Wolters Kluwer N.V.
Wolters Kluwer N.V.

Places

North America
Southern Europe
Italy
United States
Americas
Europe
Palermo
Pennsylvania
Philadelphia

Subjects

Science and Technology
      Scientific Research
Health and Wellness
      Medical Conditions and Diseases
            Cancer
                  Prostate Cancer
            Men's Health Issues
                  Prostate Cancer
      Treatments and Therapies
            Chemotherapy
            Medicinal Drugs